Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
Viking liver disease drug reduces fibrosis in final ph. 2 data
The drug reduced liver fat content by an average of 37% to 55%, with all treatment arms showing significant improvements compared to placebo.
Darren Incorvaia
Nov 20, 2024 3:20pm
NewAmsterdam’s cholesterol ph. 3 hits, but disappoints investors
Nov 20, 2024 10:07am
For Sage drug, Huntington's fail completes clean sweep of flops
Nov 20, 2024 8:35am
J&J, Protagonist's oral psoriasis prospect scores in phase 3s
Nov 19, 2024 11:44am
Lilly's lipoprotein-blocking heart drug posts midstage trial win
Nov 19, 2024 9:55am
GSK’s itch prospect hits mark in phase 3 liver disease trial
Nov 19, 2024 8:24am
